Oragenics Files 2023 Proxy Statement

TL;DR

Oragenics filed its proxy statement for the 2023 shareholder meeting. Vote your shares!

AI Summary

Oragenics, Inc. filed its definitive proxy statement (DEF 14A) on October 31, 2024, for its 2023 Annual Meeting of Shareholders. The filing provides details regarding the meeting and related matters, including information for shareholders to vote on proposals. The company is based in Sarasota, Florida, and operates in the pharmaceutical preparations sector.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and proposals for the annual meeting, allowing them to exercise their voting rights on company matters.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual shareholder meeting, not indicating immediate financial distress or significant new risks.

Key Players & Entities

• Oragenics, Inc. (company) — Registrant
• October 31, 2024 (date) — Filing Date
• 2023 (date) — Annual Meeting Year
• Sarasota, Florida (location) — Company Headquarters

FAQ

Key Financial Figures

• $12,500 — ons for the Annual Meeting for a fee of $12,500.00, plus additional fees based on the a

Filing Documents

• formdef14a.htm (DEF 14A) — 636KB
• formdef14a_001.jpg (GRAPHIC) — 7KB
• 0001493152-24-043144.txt ( ) — 646KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 Oragenics, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No Fee Required Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 1990 Main St. Suite 750 Sarasota, Florida 34236 October 31, 2024 To the Shareholders of Oragenics, Inc.: You are cordially invited to attend the 2023 Annual Meeting of Shareholders (the “ Annual Meeting ”) of Oragenics, Inc. (the “ Company ”), which will be held on December 11, 2024, beginning at 9:00 a.m. Eastern Time at the offices of Shumaker, Loop, & Kendrick, Bank of America Plaza, 101 E Kennedy Blvd Suite 2800, Tampa, FL 33602 for the following purposes: 1. To elect six Directors of the Company to serve until the next Annual Meeting of Shareholders (“ Proposal 1 ”); 2. To conduct a non-binding advisory vote on executive compensation (the “ Executive Compensation Proposal ” or “ Proposal 2 ”); 3 To approve an amendment to the Company’s 2021 Equity Incentive Plan, as amended (the “ 2021 Equity Incentive Plan ”), to increase the number of common shares available for issuance under the 2021 Equity Incentive Plan from 1,166,667 shares of Common Stock to 3,166,667 shares of Common Stock (the “ Incentive Plan Increase Proposal ” or “ Proposal 3 ”); 4. To ratify the selection of Cherry Bekaert LLP as the Company’s independent auditors for the year ending December 31, 2024 “ Proposal 4 ”); and 5. To transact such other business as may properly come before the Annual Meeting. THE BOARD UNANIMOUSLY RECOMMENDS (1) A VOTE FOR THE ELECTION OF EACH OF THE DIRECTOR NOMINEES, (2) A VOTE FOR THE APPROVAL EXECUTIVE COMPENSATION, (3) A VOTE FOR AN AMENDMENT TO THE COMPANY’S 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE UNDER THE PLAN, AND (4) A VOTE FOR THE RATIFICATION OF THE APPOINTMENT OF THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024. The Board has fixed the close of business on October 21, 2024, as the record date (the “ Record Date ”) for the determination of shareholders entitled to notice of, and to vote at, the Annual Meeting or any postponement or adjournment thereof. Accordingly, only shareholders of record at the close of business on the Record Date are entitled to notice of, and shall be entitled to vote at, the Annual Meeting or any postponement or adjournment thereof. Your vote is important. You are requested to carefully read the Proxy Statement and accompanying Notice of Annual Meeting for a more complete Sincerely, /s/ J. Michael Redmond J. Michael Redmond President Enclosures i IMPORTANT WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING, PLEASE READ THE PROXY STATEMENT AND PROMPTLY VOTE YOUR PROXY BY COMPLETING, DATING, SIGNING AND RETURNING THE ENCLOSED PROXY IN ORDER TO ASSURE REPRESENTATION OF YOUR SHARES AT THE ANNUAL MEETING. YOUR PROXY, GIVEN THROUGH THE RETURN OF THE PROXY CARD, MAY BE REVOKED PRIOR TO ITS EXERCISE BY FILING WITH OUR CORPORATE SECRETARY PRIOR TO THE ANNUAL MEETING A WRITTEN NOTICE OF REVOCATION OR A DULY EXECUTED PROXY BEARING A LATER DATE, OR BY ATTENDING THE ANNUAL MEETING AND VOTING IN PERSON. IF YOU HAVE ALREADY VOTED OR DELIVERED YOUR PROXY FOR THE ANNUAL MEETING, YOUR VOTE WILL BE COUNTED, AND YOU DO NOT HAVE TO VOTE YOUR SHARES AGAIN. IF YOU WISH TO CHANGE YOUR VOTE, YOU SHOULD REVOTE YOUR SHARES. THE PROXY STATEMENT, OUR FORM OF PROXY CARD, AND OUR ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ARE AVAILABLE ON THE INTERNET AT http://www.viewproxy.com/oragenics/2023 OR AT THE SEC’S WEBSITE AT HTTP://WWW.SEC.GOV . ii ORAGENICS, INC. 1990 Main St. Suite 750 Sarasota, Florida 34236 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 11, 2024 Notice is hereby given to the shareholders of Oragenics, Inc., a Florida Corporation (the “ Company ”), of the 2023 Annual Meeting of Shareholders of the Company (the “ Annual Meeting ”) and all adjournments and postponements thereof. The Annual Meeting will be held at the offices of Shumaker, Loop, & Kendrick, Bank of America Plaza, 101 E

View Full Filing

View this DEF 14A filing on SEC EDGAR